Condition
Refractory Myasthenia Gravis
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)
P 3 (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Terminated1
Completed1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07413835Not ApplicableRecruitingPrimary
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
NCT06965309Not ApplicableTerminatedPrimary
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
NCT07243366Early Phase 1Not Yet RecruitingPrimary
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
NCT05332587Phase 3UnknownPrimary
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT00619671Phase 1CompletedPrimary
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Showing all 5 trials